Back to top
more

Universal Health Services (UHS)

(Delayed Data from NYSE)

$187.39 USD

187.39
518,414

+1.13 (0.61%)

Updated Sep 17, 2025 04:00 PM ET

After-Market: $187.54 +0.15 (0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 13% (33 out of 245)

Industry: Medical - Hospital

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

QuidelOrtho Expands in Infectious Disease Testing With New FDA Nod

by Zacks Equity Research

QDEL announces the FDA's clearance for its VITROS syphilis assay, which boosts the company's infectious disease testing portfolio.

Zacks Equity Research

iRhythm Technologies Launches Zio Monitoring Across Europe

by Zacks Equity Research

IRTC launches Zio monitor in Austria, Netherlands, Spain and Switzerland, which offers 14-day continuous ECG monitoring, enhancing arrhythmia diagnosis and patient care.

Zacks Equity Research

Universal Health Services, Inc. (UHS) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

Universal Health Services (UHS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Nilanjan Choudhury headshot

5 Relative Price Strength Stocks That You Should Buy Now

by Nilanjan Choudhury

SNCR, MCY, UHS, VCYT and MWA are five stocks with explosive relative price strength.

Zacks Equity Research

Veeva Systems Q2 Earnings & Revenues Beat, Operating Margin Up Y/Y

by Zacks Equity Research

VEEV's fiscal second-quarter results reflect impressive performance by the Subscription services segment, along with the expansion of gross and operating margins.

Zacks Equity Research

Maravai LifeSciences' Cygnus & TriLink Unveil AccuRes DNA Kits

by Zacks Equity Research

MRVI's Cygnus and TriLink introduce AccuRes kits, setting a new standard in host cell DNA quantification with unmatched sensitivity and specificity.

Kaibalya Pravo Dey headshot

Tenet Stock Rises 24.6% in 3 Months: Is This Your Buy Signal?

by Kaibalya Pravo Dey

Despite the recent growth in stock price, THC is trading at a discount compared to the industry average.

Zacks Equity Research

Accuray Stock Rises After Helix System Wins CE Mark for Cancer Care

by Zacks Equity Research

ARAY's Helix system, now CE Mark approved, aims to close global cancer care gaps with cost-effective, high-throughput radiotherapy for underserved regions.

Zacks Equity Research

Stryker Rallies 19.8% Year to Date: What's Driving the Stock?

by Zacks Equity Research

SYK's flagship Mako Total Knee Platform, its strategic acquisitions and a diversified product portfolio raise optimism about the stock.

Zacks Equity Research

AtriCure's Shares Likely to Benefit From New AtriClip Device Sales

by Zacks Equity Research

ATRC announces the treatment of the first patient using the AtriClip FLEX-Mini device.

Zacks Equity Research

Reasons to Retain Stryker Stock in Your Portfolio for Now

by Zacks Equity Research

SYK continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio.

Zacks Equity Research

DexCom Stock May Gain on Expanded Reach After Stelo's US Launch

by Zacks Equity Research

DXCM announces that its OTC CGM, Stelo, is now available for purchase in the United States without a prescription.

Zacks Equity Research

Is HealthEquity Stock a Hold Now Amid Strong Top-Line Growth?

by Zacks Equity Research

HQY's sustained strength in HSAs raises optimism about the stock.

Zacks Equity Research

GE Healthcare to Unveil AI-Driven Cardiac Diagnostics at ESC 2024

by Zacks Equity Research

GEHC launches AI-enhanced ultrasound and ECG-less Cardiac CT technologies, offering rapid, accurate cardiac diagnostics at the point of care.

Zacks Equity Research

Reasons to Retain Fresenius Medical Stock in Your Portfolio Now

by Zacks Equity Research

FMS continues to gain traction through its broad dialysis product and service portfolio. Ongoing macro challenges raise concerns.

Zacks Equity Research

Teleflex's (TFX) Titan SGS Stapler Showcases Positive Outcomes

by Zacks Equity Research

Teleflex (TFX) publishes an analysis of clinical data showcasing the Titan SGS Stapler's enhanced clinical outcomes and significant efficiency benefits.

Zacks Equity Research

Inari Medical (NARI) Issues Notice Post ClotTriever XL Recall

by Zacks Equity Research

Inari Medical (NARI) issues urgent updates to ClotTriever XL Catheter instructions following the FDA's recall after reports of serious injuries and deaths.

Zacks Equity Research

AtriCure's (ATRC) AtriClip Receives Expanded CE-Mark Indication

by Zacks Equity Research

AtriCure (ATRC) announces the receipt of an expanded CE-Mark indication for its AtriClip devices for reducing strokes in patients with Afib.

Zacks Equity Research

Reasons to Add The Cooper Companies (COO) to Your Portfolio Now

by Zacks Equity Research

The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is, however, concerning.

Zacks Equity Research

INSPIRA (IINN) CART Gets FDA Listing, to Enhance Healthcare

by Zacks Equity Research

Inspira (IINN) announces FDA listing of its INSPIRA CART, designed for use with the ART100 system, enhancing healthcare delivery during cardiopulmonary bypass.

Zacks Equity Research

Why Is Universal Health Services (UHS) Up 11.9% Since Last Earnings Report?

by Zacks Equity Research

Universal Health Services (UHS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Stryker's (SYK) Inks Deal to Aid Its Pain Management Portfolio

by Zacks Equity Research

Stryker (SYK) is set to acquire Vertos Medical to expand its interventional pain management portfolio.

Zacks Equity Research

Inogen (INGN) Rises 127% Year to Date: What's Driving the Stock?

by Zacks Equity Research

Expanding product portfolio and high prospects for POC raise optimism for the Inogen (INGN) stock.

Zacks Equity Research

Glaukos (GKOS) Gains 63.5% YTD: What's Driving the Stock?

by Zacks Equity Research

Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.

Zacks Equity Research

Cencora (COR) Gains 16.6% YTD: What's Driving the Stock?

by Zacks Equity Research

Cencora (COR) gaining traction from the robust U.S. Healthcare Solutions segment raises optimism about the stock.